17
Aug 2026
Tagomics introduces LiquiPath, a first-in-class cfDNA-based blood test for multi-organ drug safety monitoring
Tagomics Ltd., a pioneering precision medicine company, today announced the launch of LiquiPath™, a cross-species, multi-organ "liquid pathology" platform, for non-invasive drug safety monitoring.